<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01684020</url>
  </required_header>
  <id_info>
    <org_study_id>ART-RHI-12</org_study_id>
    <nct_id>NCT01684020</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty</brief_title>
  <official_title>A Prospective, Double-Blinded, Randomized Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DeNova Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DeNova Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rhinoplasty (nasal reconstruction i.e. &quot;a nose job&quot;) is a surgical procedure performed on the&#xD;
      nose to correct a medical problem or change the appearance of the nose. During the healing&#xD;
      process, swelling and/or bruising is likely to occur. A drug called ARTISS Fibrin Sealant may&#xD;
      or may not lessen these effects. This study is looking to see the effects of ARTISS on&#xD;
      adhering tissue and improving wound healing in an external rhinoplasty. The purpose of this&#xD;
      study is to evaluate the safety and effectiveness of rhinoplasty using ARTISS compared to&#xD;
      rhinoplasty without using ARTISS in patients undergoing rhinoplasty performed through an&#xD;
      external approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2012</start_date>
  <completion_date type="Actual">April 26, 2016</completion_date>
  <primary_completion_date type="Actual">April 26, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Edema Severity</measure>
    <time_frame>Measured at Day 1, 7, 30, 180</time_frame>
    <description>Measured at Day 1, 7, 30, 180&#xD;
0 None- No apparent edema&#xD;
Mild- Minimal tissue swelling&#xD;
Moderate- Moderate edema, nasal features still discernible&#xD;
Severe- Marked swelling, difficulty distinguishing nasal features&#xD;
Scores closer to 0 indicate more favorable results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Number of Adverse Events</measure>
    <time_frame>1 day, 1 week, 4 weeks and 6 months following surgery</time_frame>
    <description>Safety will be assessed by the incidence of AEs throughout the study period as documented by clinician observations at study visits and in a 30-day subject diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blinded-assessment of Satisfaction</measure>
    <time_frame>Measured at Baseline, 1 month, 3 months, 6 months, 12 months</time_frame>
    <description>A non-treating blinded evaluator will assess satisfaction with a four-point categorical satisfaction scale [unsatisfied (4), satisfied (3), very satisfied (2), highly satisfied (1))] of subject's grafts using photographs from baseline, 1 month, 3 months, 6 months, and 12 months and will consist of a blinded evaluation in which the physician is aware of the type of graft, but unaware of plating status or the specific grafting site.&#xD;
Scores closer to 1 indicate a more favorable outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Ecchymosis Evaluation - PI</measure>
    <time_frame>6 months</time_frame>
    <description>The surface area and color of ecchymosis will be evaluated at 1 day, 1 week, 4 weeks, and 6 months following surgery.&#xD;
Rating Extent Color 0 No ecchymosis No color change&#xD;
Up to medial one-third of the lower and/or up eyelid Yellowish color change&#xD;
Medial half of the upper and/or lower eyelid Light purple&#xD;
Entire upper and/or lower eyelid Dark purple&#xD;
Entire part of the lower and upper eyelid and/or conjunctiva Very dark purple&#xD;
Extension of ecchymosis below the malar bone&#xD;
Scores closer to 0 indicate a more favorable outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Ecchymosis Evaluation - Subject</measure>
    <time_frame>6 months</time_frame>
    <description>Ecchymosis will be determined by a live assessment at 1 day, 1 week, 4 weeks and 6 months following surgery using a six-point categorical edema scale.&#xD;
Rating Extent Color 0 No ecchymosis No color change&#xD;
Up to medial one-third of the lower and/or up eyelid Yellowish color change&#xD;
Medial half of the upper and/or lower eyelid Light purple&#xD;
Entire upper and/or lower eyelid Dark purple&#xD;
Entire part of the lower and upper eyelid and/or conjunctiva Very dark purple&#xD;
Extension of ecchymosis below the malar bone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Day 30</time_frame>
    <description>Subjects will complete a 30-day diary documenting adverse events such as erythema, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching and numbness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Downtime Questionnaire</measure>
    <time_frame>1 day, 1 week, 4 weeks and 6 months following surgery</time_frame>
    <description>Subject downtime will be determined using a questionnaire at 1 day, 1 week, 4 weeks, and 6 months following surgery.&#xD;
Responders are defined as those subjects experiencing little to no downtime.&#xD;
Downtime scale:&#xD;
(3) Very Much (2) A Lot&#xD;
(1) A Little (0) Not at all&#xD;
Scores closer to 0 indicate more favorable outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPSS Assessment</measure>
    <time_frame>1 week, 4 weeks and 6 months following surgery</time_frame>
    <description>Changes in subject self-esteem will be determined by subject completion of the Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale at 1 week, 4 weeks and 6 months following surgery.&#xD;
HPSS: scored between 1-5 for 20 questions with a total possible score between 20-100&#xD;
- Not at all&#xD;
- A little bit&#xD;
- Somewhat&#xD;
- Very much&#xD;
- Extremely&#xD;
Scores closer to 100 indicate a more favorable outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Use</measure>
    <time_frame>Immediately Post Surgery</time_frame>
    <description>Ease of use will be determined by the treating investigator using a 10 cm Visual Analog Scale (VAS) to demonstrate technical ease.&#xD;
(10) - Very diffiucult - (100) - Very easy&#xD;
Scores closer to 100 indicate a more favorable outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Subjects Requesting and Requiring an Open Rhinoplasty</condition>
  <arm_group>
    <arm_group_label>ARTISS Human Fibrin Sealant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARTISS human fibrin sealant</intervention_name>
    <arm_group_label>ARTISS Human Fibrin Sealant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females between 18 and 65 years of age.&#xD;
&#xD;
          2. Subjects requesting primary rhinoplasty and requiring an external approach.&#xD;
&#xD;
          3. Subjects willing to undergo treatment with fibrin sealant.&#xD;
&#xD;
          4. Willingness and ability to comply with protocol requirements, including returning for&#xD;
             follow-up visits and abstaining from exclusionary procedures for the duration of the&#xD;
             study.&#xD;
&#xD;
          5. Willingness and ability to comply with the PI's standard preoperative and&#xD;
             postoperative rhinoplasty instructions.&#xD;
&#xD;
          6. Subjects of childbearing potential must have a negative urine pregnancy test result at&#xD;
             Visit 1 and be willing able to use an acceptable method of birth control (e.g.,&#xD;
             barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical&#xD;
             sterilization, abstinence) during the study. Women will not be considered of&#xD;
             childbearing potential if one of the following is documented on the medical history:&#xD;
&#xD;
               -  postmenopausal for at least 12 months prior to study drug administration&#xD;
&#xD;
               -  without a uterus and/or both ovaries&#xD;
&#xD;
               -  has had a bilateral tubal ligation for at least 6 months prior to study drug&#xD;
                  administration.&#xD;
&#xD;
               -  absence of an other physical condition according to the PI's discretion&#xD;
&#xD;
          7. Willingness and ability to provide written photo consent and adherence to photography&#xD;
             procedures (i.e., removal of jewelry and makeup).&#xD;
&#xD;
          8. Willingness and ability to provide written informed consent prior to performance of&#xD;
             any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a&#xD;
             reliable form of birth control.&#xD;
&#xD;
          2. Subjects who are planning a concurrent facial surgery during the operation (eg&#xD;
             forehead plasty, blepharoplasty, rhinoplasty, buccal fat removal, any filler&#xD;
             injections including fat injections, lip augmentation, skin resurfacing procedures&#xD;
             etc.).&#xD;
&#xD;
          3. Subjects with a previous history of rhinoplasty.&#xD;
&#xD;
          4. Subjects with a current history of smoking.&#xD;
&#xD;
          5. Subjects with a previous history of a bleeding or coagulation disorder .&#xD;
&#xD;
          6. Subject with a previous history of a vascular disorder, cardiovascular disease, and/or&#xD;
             uncontrolled hypertension.&#xD;
&#xD;
          7. Subjects a previous history of diabetes mellitus with glycosylated hemoglobin (HbA1c)&#xD;
             &gt; 7.&#xD;
&#xD;
          8. Subjects undergoing active treatment for a malignancy.&#xD;
&#xD;
          9. Subjects with a previous history of has a connective tissue disorder.&#xD;
&#xD;
         10. Subjects with active or chronic skin disorder.&#xD;
&#xD;
         11. Subjects with a previous history of Bell's palsy.&#xD;
&#xD;
         12. Subjects with a previous history of pathologically or pharmacologically induced immune&#xD;
             deficiency.&#xD;
&#xD;
         13. Subjects who have received chronic treatment with immunosuppressive drugs, systemic&#xD;
             corticosteroids, or other chronic treatments within 30 days prior to the surgery.&#xD;
&#xD;
         14. Subjects with a known sensitivity to components of FS VH S/D 4 s-apr.&#xD;
&#xD;
         15. Subjects with a previous history of healing complications following previous surgeries&#xD;
             (eg, hypertrophic scarring).&#xD;
&#xD;
         16. Subjects with a significant systemic illness or illness localized to the areas of&#xD;
             treatment.&#xD;
&#xD;
         17. Subjects with previous history of nasal implants.&#xD;
&#xD;
         18. Subjects with previous or current history of nasal infections.&#xD;
&#xD;
         19. Subjects who have history of blood thinners (aspirin, ibuprofen, naprosyn, herbal&#xD;
             supplements, Vitamin E) within the two weeks prior to surgery.&#xD;
&#xD;
         20. Subjects who have smoked within the two weeks prior to surgery.&#xD;
&#xD;
         21. Subjects who have had alcohol or illicit drugs one week prior to surgery.&#xD;
&#xD;
         22. Subjects who have eaten or drank anything after midnight the night prior to surgery.&#xD;
&#xD;
         23. Subjects with current history of chronic drug or alcohol abuse.&#xD;
&#xD;
         24. Concurrent therapy that, in the investigator's opinion, would interfere with the&#xD;
             evaluation of the safety or efficacy of the study medication.&#xD;
&#xD;
         25. Subjects who anticipate the need for surgery, other than the study procedure, or&#xD;
             overnight hospitalization during the study.&#xD;
&#xD;
         26. Subjects who, in the Investigator's opinion, have a history of poor cooperation, non&#xD;
             compliance with medical treatment or unreliability.&#xD;
&#xD;
         27. Subject has participated in another clinical study involving an investigational&#xD;
             product/device within 30 days prior to enrollment or is scheduled to participate in&#xD;
             another clinical study involving an investigational product/device during the course&#xD;
             of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven H Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DeNova Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.denovaresearch.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 7, 2012</study_first_submitted>
  <study_first_submitted_qc>September 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2012</study_first_posted>
  <results_first_submitted>August 11, 2020</results_first_submitted>
  <results_first_submitted_qc>September 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>DeNova Research</investigator_affiliation>
    <investigator_full_name>Steven H. Dayan</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>rhinoplasty</keyword>
  <keyword>external rhinoplasty</keyword>
  <keyword>open rhinoplasty</keyword>
  <keyword>nose job</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ARTISS Human Fibrin Sealant</title>
          <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ARTISS Human Fibrin Sealant</title>
          <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="B2" value="45.3" lower_limit="18" upper_limit="50"/>
                    <measurement group_id="B3" value="45.3" lower_limit="18" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Edema Severity</title>
        <description>Measured at Day 1, 7, 30, 180&#xD;
0 None- No apparent edema&#xD;
Mild- Minimal tissue swelling&#xD;
Moderate- Moderate edema, nasal features still discernible&#xD;
Severe- Marked swelling, difficulty distinguishing nasal features&#xD;
Scores closer to 0 indicate more favorable results</description>
        <time_frame>Measured at Day 1, 7, 30, 180</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARTISS Human Fibrin Sealant</title>
            <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Edema Severity</title>
          <description>Measured at Day 1, 7, 30, 180&#xD;
0 None- No apparent edema&#xD;
Mild- Minimal tissue swelling&#xD;
Moderate- Moderate edema, nasal features still discernible&#xD;
Severe- Marked swelling, difficulty distinguishing nasal features&#xD;
Scores closer to 0 indicate more favorable results</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.5"/>
                    <measurement group_id="O2" value="1.5" spread="1.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.5"/>
                    <measurement group_id="O2" value="1" spread="1.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.816"/>
                    <measurement group_id="O2" value="1" spread="1.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.5"/>
                    <measurement group_id="O2" value="0.5" spread="0.577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Number of Adverse Events</title>
        <description>Safety will be assessed by the incidence of AEs throughout the study period as documented by clinician observations at study visits and in a 30-day subject diary.</description>
        <time_frame>1 day, 1 week, 4 weeks and 6 months following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARTISS Human Fibrin Sealant</title>
            <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Adverse Events</title>
          <description>Safety will be assessed by the incidence of AEs throughout the study period as documented by clinician observations at study visits and in a 30-day subject diary.</description>
          <units>number of AE's</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="10" lower_limit="8" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blinded-assessment of Satisfaction</title>
        <description>A non-treating blinded evaluator will assess satisfaction with a four-point categorical satisfaction scale [unsatisfied (4), satisfied (3), very satisfied (2), highly satisfied (1))] of subject's grafts using photographs from baseline, 1 month, 3 months, 6 months, and 12 months and will consist of a blinded evaluation in which the physician is aware of the type of graft, but unaware of plating status or the specific grafting site.&#xD;
Scores closer to 1 indicate a more favorable outcome</description>
        <time_frame>Measured at Baseline, 1 month, 3 months, 6 months, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARTISS Human Fibrin Sealant</title>
            <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Blinded-assessment of Satisfaction</title>
          <description>A non-treating blinded evaluator will assess satisfaction with a four-point categorical satisfaction scale [unsatisfied (4), satisfied (3), very satisfied (2), highly satisfied (1))] of subject's grafts using photographs from baseline, 1 month, 3 months, 6 months, and 12 months and will consist of a blinded evaluation in which the physician is aware of the type of graft, but unaware of plating status or the specific grafting site.&#xD;
Scores closer to 1 indicate a more favorable outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="0"/>
                    <measurement group_id="O2" value="4" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.894"/>
                    <measurement group_id="O2" value="2" spread="0.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.894"/>
                    <measurement group_id="O2" value="1.33" spread="0.577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.707"/>
                    <measurement group_id="O2" value="2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Ecchymosis Evaluation - PI</title>
        <description>The surface area and color of ecchymosis will be evaluated at 1 day, 1 week, 4 weeks, and 6 months following surgery.&#xD;
Rating Extent Color 0 No ecchymosis No color change&#xD;
Up to medial one-third of the lower and/or up eyelid Yellowish color change&#xD;
Medial half of the upper and/or lower eyelid Light purple&#xD;
Entire upper and/or lower eyelid Dark purple&#xD;
Entire part of the lower and upper eyelid and/or conjunctiva Very dark purple&#xD;
Extension of ecchymosis below the malar bone&#xD;
Scores closer to 0 indicate a more favorable outcome.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARTISS Human Fibrin Sealant</title>
            <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Ecchymosis Evaluation - PI</title>
          <description>The surface area and color of ecchymosis will be evaluated at 1 day, 1 week, 4 weeks, and 6 months following surgery.&#xD;
Rating Extent Color 0 No ecchymosis No color change&#xD;
Up to medial one-third of the lower and/or up eyelid Yellowish color change&#xD;
Medial half of the upper and/or lower eyelid Light purple&#xD;
Entire upper and/or lower eyelid Dark purple&#xD;
Entire part of the lower and upper eyelid and/or conjunctiva Very dark purple&#xD;
Extension of ecchymosis below the malar bone&#xD;
Scores closer to 0 indicate a more favorable outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1"/>
                    <measurement group_id="O2" value="1.5" spread="0.577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.548"/>
                    <measurement group_id="O2" value="0.75" spread="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Ecchymosis Evaluation - Subject</title>
        <description>Ecchymosis will be determined by a live assessment at 1 day, 1 week, 4 weeks and 6 months following surgery using a six-point categorical edema scale.&#xD;
Rating Extent Color 0 No ecchymosis No color change&#xD;
Up to medial one-third of the lower and/or up eyelid Yellowish color change&#xD;
Medial half of the upper and/or lower eyelid Light purple&#xD;
Entire upper and/or lower eyelid Dark purple&#xD;
Entire part of the lower and upper eyelid and/or conjunctiva Very dark purple&#xD;
Extension of ecchymosis below the malar bone</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARTISS Human Fibrin Sealant</title>
            <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Ecchymosis Evaluation - Subject</title>
          <description>Ecchymosis will be determined by a live assessment at 1 day, 1 week, 4 weeks and 6 months following surgery using a six-point categorical edema scale.&#xD;
Rating Extent Color 0 No ecchymosis No color change&#xD;
Up to medial one-third of the lower and/or up eyelid Yellowish color change&#xD;
Medial half of the upper and/or lower eyelid Light purple&#xD;
Entire upper and/or lower eyelid Dark purple&#xD;
Entire part of the lower and upper eyelid and/or conjunctiva Very dark purple&#xD;
Extension of ecchymosis below the malar bone</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1"/>
                    <measurement group_id="O2" value="2" spread="0.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.667"/>
                    <measurement group_id="O2" value="2" spread="0.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Subjects will complete a 30-day diary documenting adverse events such as erythema, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching and numbness.</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARTISS Human Fibrin Sealant</title>
            <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Subjects will complete a 30-day diary documenting adverse events such as erythema, pain, tenderness, firmness, swelling, lumps/bumps, bruising, itching and numbness.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Downtime Questionnaire</title>
        <description>Subject downtime will be determined using a questionnaire at 1 day, 1 week, 4 weeks, and 6 months following surgery.&#xD;
Responders are defined as those subjects experiencing little to no downtime.&#xD;
Downtime scale:&#xD;
(3) Very Much (2) A Lot&#xD;
(1) A Little (0) Not at all&#xD;
Scores closer to 0 indicate more favorable outcome</description>
        <time_frame>1 day, 1 week, 4 weeks and 6 months following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARTISS Human Fibrin Sealant</title>
            <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Downtime Questionnaire</title>
          <description>Subject downtime will be determined using a questionnaire at 1 day, 1 week, 4 weeks, and 6 months following surgery.&#xD;
Responders are defined as those subjects experiencing little to no downtime.&#xD;
Downtime scale:&#xD;
(3) Very Much (2) A Lot&#xD;
(1) A Little (0) Not at all&#xD;
Scores closer to 0 indicate more favorable outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.864"/>
                    <measurement group_id="O2" value="4" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.447"/>
                    <measurement group_id="O2" value="3.25" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.14"/>
                    <measurement group_id="O2" value="2" spread="0.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.447"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPSS Assessment</title>
        <description>Changes in subject self-esteem will be determined by subject completion of the Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale at 1 week, 4 weeks and 6 months following surgery.&#xD;
HPSS: scored between 1-5 for 20 questions with a total possible score between 20-100&#xD;
- Not at all&#xD;
- A little bit&#xD;
- Somewhat&#xD;
- Very much&#xD;
- Extremely&#xD;
Scores closer to 100 indicate a more favorable outcome</description>
        <time_frame>1 week, 4 weeks and 6 months following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARTISS Human Fibrin Sealant</title>
            <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>HPSS Assessment</title>
          <description>Changes in subject self-esteem will be determined by subject completion of the Heatherton &amp; Polivy State Self-Esteem (HPSS) Scale at 1 week, 4 weeks and 6 months following surgery.&#xD;
HPSS: scored between 1-5 for 20 questions with a total possible score between 20-100&#xD;
- Not at all&#xD;
- A little bit&#xD;
- Somewhat&#xD;
- Very much&#xD;
- Extremely&#xD;
Scores closer to 100 indicate a more favorable outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.447"/>
                    <measurement group_id="O2" value="3.25" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.14"/>
                    <measurement group_id="O2" value="2" spread="0.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.447"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ease of Use</title>
        <description>Ease of use will be determined by the treating investigator using a 10 cm Visual Analog Scale (VAS) to demonstrate technical ease.&#xD;
(10) - Very diffiucult - (100) - Very easy&#xD;
Scores closer to 100 indicate a more favorable outcome</description>
        <time_frame>Immediately Post Surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARTISS Human Fibrin Sealant</title>
            <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
          </group>
        </group_list>
        <measure>
          <title>Ease of Use</title>
          <description>Ease of use will be determined by the treating investigator using a 10 cm Visual Analog Scale (VAS) to demonstrate technical ease.&#xD;
(10) - Very diffiucult - (100) - Very easy&#xD;
Scores closer to 100 indicate a more favorable outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="5.225"/>
                    <measurement group_id="O2" value="39" spread="17.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ARTISS Human Fibrin Sealant</title>
          <description>Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.&#xD;
ARTISS human fibrin sealant</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Fixation of the skin flap created during external rhinoplasty will use the standard of care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <description>A discoloration of the skin resulting from bleeding underneath, typically caused by bruising</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Dayan, MD</name_or_title>
      <organization>DeNova Research</organization>
      <phone>3123352070</phone>
      <email>sdayan@drdayan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

